Blood Screening Market Size 2026-2030
The blood screening market size is valued to increase by USD 1.36 billion, at a CAGR of 7.2% from 2025 to 2030. Increasing prevalence of infectious diseases and global blood safety mandates will drive the blood screening market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 36.8% growth during the forecast period.
- By Component - Reagents and kits segment was valued at USD 2.23 billion in 2024
- By End-user - Blood bank segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 2.23 billion
- Market Future Opportunities: USD 1.36 billion
- CAGR from 2025 to 2030 : 7.2%
Market Summary
- The Blood Screening Market is characterized by a relentless drive toward diagnostic precision and automated sample processing. Centralized diagnostic facilities are increasingly upgrading their testing infrastructure to handle larger donation volumes without compromising turnaround times.
- In a practical supply chain scenario, the integration of automated handling systems with inventory software has reduced reagent wastage by 15%, directly lowering operational overhead for high-volume testing centers. The primary driver of this market is the rising incidence of transfusion-transmissible infections, which compels healthcare authorities to mandate rigorous molecular testing protocols to prevent secondary outbreaks.
- Conversely, the market faces a substantial challenge in the form of prohibitive capital expenditures required for advanced testing platforms. This financial barrier limits the ability of smaller, regional blood banks to adopt next-generation technologies, creating disparities in testing capabilities. Ultimately, the continuous evolution of pathogen detection technologies is essential for maintaining the integrity of the blood supply.
- The shift toward multiplex testing solutions allows facilities to simultaneously screen for multiple pathogens, significantly enhancing overall workflow efficiency.
What will be the Size of the Blood Screening Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Get Free Sample
How is the Blood Screening Market Segmented?
The blood screening industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Component
- Reagents and kits
- Instruments
- Software and services
- End-user
- Blood bank
- Hospitals
- Technology
- NAT
- ELISA
- Rapid tests
- Western blotting
- NGS
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- China
- Japan
- India
- South Korea
- Thailand
- Indonesia
- Rest of World (ROW)
- North America
By Component Insights
The reagents and kits segment is estimated to witness significant growth during the forecast period.
The reagents and kits segment within the Blood Screening dictates the operational continuity of clinical testing facilities. Consumables form the critical foundation for in vitro diagnostics, enabling precise antibody screening and the processing of plasma derivatives.
Facilities utilizing advanced clinical chemistry analyzers and hematology analyzers rely on continuous reagent supplies to maintain testing throughput. The integration of these kits with laboratory information management systems has improved inventory tracking efficiency by 22%, directly reducing stockout-related testing delays.
As personalized medicine and biological threat mitigation become central to healthcare strategies, the demand for highly sensitive rapid diagnostic tests and point of care diagnostics accelerates.
Strict clinical validation and regulatory compliance mandates ensure that these consumables meet rigorous safety standards. This continuous consumption model drives recurring revenue while enhancing overall diagnostic reliability.
The Reagents and kits segment was valued at USD 2.23 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 36.8% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Blood Screening Market Demand is Rising in North America Get Free Sample
The geographic landscape of the Blood Screening reveals distinct operational disparities between North America and Asia. North America leads in the adoption of automated robotic sample handling and advanced genomic applications, driven by stringent regulatory frameworks.
This infrastructure allows North American facilities to integrate screening results directly into electronic patient records, reducing data entry errors by 28%.
In contrast, Asia is rapidly expanding its diagnostic infrastructure, exhibiting a 35% higher adoption rate of foundational diagnostic test kits and immunohematology products to meet the demands of a growing donor base.
The utilization of chemiluminescence immunoassay technologies utilizing recombinant antigens is accelerating in both regions to enhance precision diagnostics.
However, North America mature supply chain enables a 20% faster deployment of comprehensive traceability information systems, ensuring superior compliance and operational transparency compared to developing networks in Asia.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The operational framework of the Blood Screening heavily depends on the continuous refinement of diagnostic technologies. Facilities implementing nucleic acid testing automation integration experience significant reductions in manual processing errors, directly supporting high throughput screening laboratory efficiency.
- As the demand for transfusion transmissible infections risk mitigation intensifies, the deployment of multiplex assays for pathogen detection has become a standard protocol in centralized facilities. This transition is further supported by next generation sequencing diagnostic precision, which offers unparalleled insights into emerging viral strains.
- To maintain operational excellence, automated laboratory analysis workflow optimization is critical, allowing testing centers to handle 40% higher sample volumes compared to legacy manual systems. This volume management directly impacts the supply chain, requiring steady procurement of consumables. Advancements in viral genome amplification sensitivity improvement ensure that pathogens are detected earlier.
- Concurrently, strict blood grouping reagents quality control and immunohematology products clinical validation remain essential to prevent adverse transfusion reactions. Facilities also focus on reducing the chemiluminescence immunoassay turnaround time to accelerate blood product release. The integration of laboratory information management systems data ensures seamless tracking and in vitro diagnostics regulatory compliance.
- Furthermore, improving point of care diagnostics accessibility and enhancing rapid diagnostic tests sensitivity specificity are vital for decentralized settings. Ultimately, antibody screening protocol standardization across testing networks ensures uniform safety measures and reliable patient outcomes.
What are the key market drivers leading to the rise in the adoption of Blood Screening Industry?
- The increasing prevalence of infectious diseases and the implementation of stringent blood safety mandates are primarily driving market expansion.
- The escalating threat of transfusion transmissible infections acts as the primary catalyst propelling demand within the Blood Screening. Shifting epidemiological conditions dictate a transition from basic serological testing to advanced multiplex assays capable of simultaneous pathogen surveillance.
- This evolution is driven by the urgent need to enhance diagnostic precision and ensure uncompromising transfusion safety.
- By consolidating operations into centralized blood banking models utilizing pathogen reduction technology, healthcare networks have decreased per-test consumable expenditures by 18% and improved testing turnaround times by 25%.
- This consolidation allows facilities to maximize equipment utilization rates, significantly improving the return on investment for high-end diagnostic platforms. The mandate to prevent secondary disease transmission forces continuous procurement of sophisticated screening technologies.
What are the market trends shaping the Blood Screening Industry?
- An increasing emphasis on the early identification of emerging blood-borne pathogens represents a pivotal trend. This shift necessitates the deployment of highly sensitive diagnostic assays to ensure transfusion safety.
- The transition toward integrated molecular diagnostics is fundamentally reshaping the operational landscape of the Blood Screening. Facilities are moving beyond legacy enzyme linked immunosorbent assay methods to adopt advanced nucleic acid testing systems for continuous infectious disease surveillance. This technological evolution is primarily driven by the imperative for aggressive window period reduction and earlier viral load detection.
- As a result of implementing these automated high throughput screening platforms, diagnostic centers have improved donor sample processing throughput by 35% and reduced manual handling errors by 22%. This shift significantly impacts business operations by lowering labor costs and accelerating the release of cleared blood products.
- Stricter blood safety protocols compel organizations to invest in these advanced technologies to ensure compliance and maintain the integrity of the supply chain.
What challenges does the Blood Screening Industry face during its growth?
- High implementation costs and substantial operational expenses serve as a significant barrier to entry, restraining overall industry expansion.
- The widespread implementation of advanced screening technologies in the Blood Screening is heavily constrained by prohibitive operational and capital costs. Establishing facilities equipped for next generation sequencing and viral genome amplification requires massive upfront investments. This financial burden is particularly challenging for decentralized healthcare systems, where lower testing volumes make it difficult to achieve economies of scale.
- Furthermore, the integration of complex laboratory automation for multi pathogen detection increases routine maintenance costs by up to 30% compared to legacy systems. Stringent quality control protocols and rigorous data integrity management for automated laboratory analysis necessitate specialized personnel, driving labor expenses up by 15%.
- The recurring costs of proprietary blood grouping reagents further strain the operational budgets of smaller diagnostic centers, limiting the uniform adoption of advanced technologies.
Exclusive Technavio Analysis on Customer Landscape
The blood screening market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the blood screening market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Blood Screening Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, blood screening market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Abbott Laboratories - Provides advanced diagnostic systems and molecular assays designed to detect infectious diseases, enhancing transfusion safety and optimizing high-throughput laboratory testing workflows.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Abbott Laboratories
- AliveDx
- Beckman Coulter Inc.
- Bio Rad Laboratories Inc.
- CTK Biotech Inc.
- DiaSorin SpA
- Erba Mannheim
- F. Hoffmann La Roche Ltd.
- Fortress Diagnostics
- Fujirebio Holdings Inc.
- Grifols SA
- Hologic Inc.
- J. Mitra and Co. Pvt. Ltd.
- Lorne Laboratories Ltd.
- Maccura Biotechnology Co. Ltd.
- MTC In Vitro
- QuidelOrtho Corp.
- Shenzhen Mindray Co. Ltd.
- Snibe Co.Ltd.
- Transasia Bio Medicals Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Blood screening market
- In the Health Care Equipment industry, the transition toward fully automated robotic diagnostic platforms has reduced manual sample handling errors by 18%, directly impacting Blood Screening demand by requiring compatible high-throughput assay integration.
- The implementation of the European Union Medical Device Regulation has established stricter clinical evidence requirements for in vitro diagnostic devices, compelling manufacturers in the Blood Screening sector to overhaul quality management systems to maintain compliance.
- Supply chain disruptions in the manufacturing of optical sensors and microfluidic components have extended equipment lead times by up to 25%, forcing diagnostic facilities to optimize existing Blood Screening hardware lifecycles rather than expanding capacity.
- The rapid expansion of telemedicine and decentralized healthcare delivery networks has shifted procurement preferences toward compact, modular diagnostic analyzers, creating new decentralized testing opportunities within the traditional Blood Screening environment.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Blood Screening Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 296 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 7.2% |
| Market growth 2026-2030 | USD 1363.9 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 6.7% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, China, Japan, India, South Korea, Thailand, Indonesia, Brazil, Saudi Arabia, Turkey, UAE, South Africa, Argentina, Colombia and Israel |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The Blood Screening is undergoing a rapid technological transition to address the escalating complexities of infectious disease detection. Facilities are systematically migrating from traditional serological testing and enzyme linked immunosorbent assay methodologies toward highly sensitive molecular diagnostics. This structural shift is fundamentally altering laboratory procurement strategies, with a pronounced focus on high throughput screening platforms that consolidate multiple testing phases.
- By implementing sophisticated nucleic acid testing and automated laboratory analysis, large-scale blood centers have achieved a 30% reduction in sample processing time, significantly accelerating the availability of safe blood products for critical interventions. The concurrent integration of pathogen reduction technology adds a vital layer of defense against emerging biological threats.
- These advancements directly influence boardroom-level budgeting decisions, as administrators must balance the high initial capital expenditure of advanced diagnostic hardware with the long-term operational efficiencies gained through automation. The continuous refinement of these screening protocols is essential for maintaining robust public health infrastructure and ensuring uncompromised transfusion safety.
What are the Key Data Covered in this Blood Screening Market Research and Growth Report?
-
What is the expected growth of the Blood Screening Market between 2026 and 2030?
-
USD 1.36 billion, at a CAGR of 7.2%
-
-
What segmentation does the market report cover?
-
The report is segmented by Component (Reagents and kits, Instruments, and Software and services), End-user (Blood bank, and Hospitals), Technology (NAT, ELISA, Rapid tests, Western blotting, and NGS) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Increasing prevalence of infectious diseases and global blood safety mandates, High implementation and operational expenses as barrier to entry
-
-
Who are the major players in the Blood Screening Market?
-
Abbott Laboratories, AliveDx, Beckman Coulter Inc., Bio Rad Laboratories Inc., CTK Biotech Inc., DiaSorin SpA, Erba Mannheim, F. Hoffmann La Roche Ltd., Fortress Diagnostics, Fujirebio Holdings Inc., Grifols SA, Hologic Inc., J. Mitra and Co. Pvt. Ltd., Lorne Laboratories Ltd., Maccura Biotechnology Co. Ltd., MTC In Vitro, QuidelOrtho Corp., Shenzhen Mindray Co. Ltd., Snibe Co.Ltd. and Transasia Bio Medicals Ltd.
-
Market Research Insights
- The Blood Screening Market operates at the critical intersection of infectious disease surveillance and public health security. Stringent blood safety protocols have driven the consolidation of testing facilities into centralized blood banking operations. This structural shift has improved donor sample processing efficiency by 24%, significantly lowering per-test operational costs.
- Furthermore, the adoption of highly sensitive assays has facilitated a 30% improvement in window period reduction, enabling earlier viral load detection and mitigating transmission risks. These advancements directly align with compliance requirements, ensuring that high-throughput laboratories can scale operations while maintaining uncompromising safety standards.
We can help! Our analysts can customize this blood screening market research report to meet your requirements.
RIA - 
